Immunogene therapy for glioblastoma
The goal of the project is to establish a new immunogene therapy. We are about to validate interesting cytokine candidates together with the suicide gene therapy experimentally. We have filled out a DOFI about this new therapy and sent it to BTO. At this stage "brukermedvirkning" is not relevant, but might become relevant when/if we enter the clinical phase of development. There is still a long way to go as we first need to verify combination therapy experimentally. When/If the patent is filed, we can start to attract investors in order to be able to move to clinical translation of the product.